Patrick Wood

1.8k citations

34 papers · 1.4k · 1 hit paper · h-index 14

Impact in

Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment
Biochemistry top 5%
- Blood transfusion and management

Papers in

Pathology and Forensic Medicine 9
- Lymphoma Diagnosis and Treatment 9
Biochemistry 4
- Blood transfusion and management 4

Co-authors: Samar Issa (8 shared papers)David Simpson (9 shared papers)David A. Macdonald (7 shared papers)Kathryn S. Kolibaba (7 shared papers)John M. Burke (7 shared papers)Ian W. Flinn (7 shared papers)Brad S. Kahl (6 shared papers)Richard van der Jagt (4 shared papers)
Journals: Blood (6 papers)British Journal of Haematology (3 papers)Hematological Oncology (2 papers)Emergency Medicine Australasia (2 papers)BMC Cancer (1 paper)
Partner nations: Australia New Zealand United States

In The Last Decade

Patrick Wood

34 papers receiving 1.4k citations

Patrick Wood's Hit Papers

align trajectories log scale

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study 2014 · 517 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2014 Blood

Peers

Countries citing papers authored by Patrick Wood

Since Specialization

Citations

This map shows the geographic impact of Patrick Wood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Wood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Wood more than expected).

Fields of papers citing papers by Patrick Wood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Wood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Wood. The network helps show where Patrick Wood may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Wood, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Wood Line = papers co-authored together Patrick Wood links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study Blood ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Patrick Wood, David A. Macdonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson Hit paper breakdown →	2014	517
2	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study Journal of Clinical Oncology ·Ian W. Flinn, Richard van der Jagt, Brad S. Kahl, Patrick Wood, David A. Macdonald, David Simpson, Kathryn S. Kolibaba, Samar Issa	2019	228
3	New oral anticoagulants: a practical guide on prescription, laboratory testing and peri‐procedural/bleeding management Internal Medicine Journal ·Joanne Emily Joseph, Simon J. McRae, Jennifer L. Curnow, Harshal H. Nandurkar, Patrick Wood, Claire McLintock +2 others	2014	128
4	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma Clinical Cancer Research ·Colm Keane, Clare Gould, Kimberley Jones, David E. Hamm, Dipti Talaulikar, Jonathan J. Ellis, Frank Vari, Simone E. Birch	2016	71
5	Age of blood and recipient factors determine the severity of transfusion-related acute lung injury (TRALI) Critical Care ·John‐Paul Tung, John Francis Fraser, Maria I. Nataatmadja, Kathryn I Colebourne, Adrian Gerard Barnett, Kristen Glenister, Anna Y. Zhou, Patrick Wood	2012	63
6	A novel in vivo ovine model of transfusion‐related acute lung injury (TRALI) Vox Sanguinis ·John‐Paul Tung, Yoke Lin Fung, Maria I. Nataatmadja, Kathryn I Colebourne, Hend M. Esmaeel, Adrian Gerard Barnett, Patrick Wood, Christopher C. Silliman	2010	55
7	Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non‐Hodgkin's lymphoma Genes Chromosomes and Cancer ·Carlos Aya‐Bonilla, Maher K. Gandhi, Rod A. Lea, Jeremy Wellwood, Patrick Wood, Paula V. Marlton, Lyn Robyn Griffiths +1 other	2011	46
8	Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience British Journal of Haematology ·Katharine Louise Lewis, Collin K. Chin, Kate Manos, John Casey, Nada Hamad, Julie H. Crawford, Shir‐Jing Ho, Samar Issa	2020	41
9	Platelet–monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab International Journal of Cardiology ·Michael J. Ray, D. Walters, J. H. N. Bett, James D. Cameron, Patrick Wood, Con N Aroney	2004	32
10	An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study Blood ·Ian W. Flinn, Richard HC van der Jagt, Brad S. Kahl, Patrick Wood, David A. Macdonald, Mark Hertzberg, Yiu‐Lam Kwan, David Simpson	2012	27
11	Respiratory burst function of ovine neutrophils BMC Immunology ·John‐Paul Tung, John Francis Fraser, Patrick Wood, Yoke Lin Fung	2009	21
12	The systemic inflammatory response syndrome induces functional changes and relative hyporesponsiveness in neutrophils Journal of Critical Care ·Yoke Lin Fung, John Francis Fraser, Patrick Wood, Robyn M. Minchinton, Christopher C. Silliman	2008	18
13	Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Clinical Lymphoma Myeloma & Leukemia ·John M. Burke, Richard H. C. Van Der Jagt, Brad S. Kahl, Patrick Wood, David A. Macdonald, Mark Hertzberg, David Simpson, Michael Craig	2016	18
14	BRUTON'S TYROSINE KINASE (BTK) INHIBITOR BGB‐3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) Hematological Oncology ·Judith Trotman, Stephen Opat, Paula V. Marlton, David J. Gottlieb, David Simpson, Gavin Cull, David Ritchie, Emma Verner	2017	15
15	Assessment of Maintenance Rituximab after First-Line Bendamustine-Rituximab in Patients with Follicular Lymphoma: An Analysis from the BRIGHT Trial Blood ·Brad S. Kahl, John M. Burke, Richard van der Jagt, Julie E Chang, Patrick Wood, David A. Macdonald, Judith Trotman, David Simpson	2017	14
16	CARDIOPULMONARY BYPASS INDUCES ENDURING ALTERATIONS TO HOST NEUTROPHIL PHYSIOLOGY Shock ·Yoke Lin Fung, Christopher C. Silliman, Robyn M. Minchinton, Patrick Wood, John Francis Fraser	2008	13
17	High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study Blood ·Constantine Si Lun Tam, Judith Trotman, Stephen Opat, Paula V. Marlton, Gavin Cull, David Simpson, Matthew Ku, David Ritchie	2016	12
18	FIRST‐LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R‐CHOP/R‐CVP: RESULTS OF THE BRIGHT 5‐YEAR FOLLOW‐UP STUDY Hematological Oncology ·Ian W. Flinn, Richard van der Jagt, Julie E Chang, Patrick Wood, Taylor Dee Hawkins, David A. Macdonald, Judith Trotman, David Simpson	2017	9
19	Point‐of‐care testing shows clinically relevant variation in the degree of inhibition of platelets by standard‐dose abciximab therapy during percutaneous coronary intervention Catheterization and Cardiovascular Interventions ·Michael J. Ray, D. Walters, Nicholas Bett, James D. Cameron, Patrick Wood, Con N Aroney	2004	7
20	A new method to detect loss of heterozygosity using cohort heterozygosity comparisons BMC Cancer ·Paul Jardine, Patrick Wood, Jeremy Wellwood, Rod A. Lea, Paula V. Marlton, Lyn Robyn Griffiths +1 other	2010	7

About Patrick Wood

Patrick Wood is a scholar working on Pathology and Forensic Medicine, Biochemistry, Cardiology and Cardiovascular Medicine, Immunology and Genetics, having authored 34 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (9 papers), Blood transfusion and management (4 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (3 papers), Antiplatelet Therapy and Cardiovascular Diseases (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Atrial Fibrillation Management and Outcomes (2 papers), Liver Disease and Transplantation (2 papers) and Acute Myeloid Leukemia Research (1 paper). The work is most often cited by research in Pathology and Forensic Medicine (705 citations), Biochemistry (105 citations), Genetics (63 citations), Internal Medicine (19 citations) and Cardiology and Cardiovascular Medicine (73 citations). Patrick Wood has collaborated with scholars based in Australia, New Zealand and United States. Frequent co-authors include Samar Issa, David Simpson, David A. Macdonald, Kathryn S. Kolibaba, John M. Burke, Ian W. Flinn, Brad S. Kahl, Richard van der Jagt, Doreen M. Hallman and Mihaela C. Munteanu. Their work appears in journals such as Blood, British Journal of Haematology, Hematological Oncology, Emergency Medicine Australasia and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Patrick Wood

Impact in

Papers in i

In The Last Decade

Patrick Wood

Patrick Wood's Hit Papers

Peers

Countries citing papers authored by Patrick Wood

Fields of papers citing papers by Patrick Wood

All Works

About Patrick Wood

Explore authors with similar magnitude of impact

Papers in